- Home
- RZLV vs CSTL Comparison
RZLV vs CSTL Comparison
Compare RZLV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLV
- CSTL
- Stock Information
- Founded
- RZLV 2016
- CSTL 2007
- Country
- RZLV United Kingdom
- CSTL United States
- Employees
- RZLV N/A
- CSTL 761
- Industry
- RZLV
- CSTL Medical Specialities
- Sector
- RZLV
- CSTL Health Care
- Exchange
- RZLV NYSE
- CSTL Nasdaq
- Market Cap
- RZLV 697.4M
- CSTL 558.7M
- IPO Year
- RZLV N/A
- CSTL 2019
- Fundamental
- Price
- RZLV $2.03
- CSTL $16.79
- Analyst Decision
- RZLV Strong Buy
- CSTL Strong Buy
- Analyst Count
- RZLV 5
- CSTL 6
- Target Price
- RZLV $5.20
- CSTL $38.33
- AVG Volume (30 Days)
- RZLV 5.9M
- CSTL 540.5K
- Earning Date
- RZLV 02-21-2025
- CSTL 05-05-2025
- Dividend Yield
- RZLV N/A
- CSTL N/A
- EPS Growth
- RZLV N/A
- CSTL N/A
- EPS
- RZLV N/A
- CSTL N/A
- Revenue
- RZLV $187,788.00
- CSTL $347,083,000.00
- Revenue This Year
- RZLV $18,130.13
- CSTL N/A
- Revenue Next Year
- RZLV $184.28
- CSTL $3.14
- P/E Ratio
- RZLV N/A
- CSTL N/A
- Revenue Growth
- RZLV 29.46
- CSTL 38.43
- 52 Week Low
- RZLV $1.07
- CSTL $15.70
- 52 Week High
- RZLV $14.50
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- RZLV N/A
- CSTL 31.31
- Support Level
- RZLV N/A
- CSTL $15.70
- Resistance Level
- RZLV N/A
- CSTL $17.70
- Average True Range (ATR)
- RZLV 0.00
- CSTL 1.06
- MACD
- RZLV 0.00
- CSTL -0.36
- Stochastic Oscillator
- RZLV 0.00
- CSTL 15.25
About RZLV REZOLVE AI LTD
Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.